Biosafety Guidelines For Research On Genetically Modified ...

More documents

Recommendations

Info

tanks and freezers. Laboratory personnel who leave the laboratory for new employment shall ensure that these materials are either discarded or entrusted to another worker. A central register shall be maintained which includes a record of stored cell lines and human-infectious viruses. Principal Investigators are responsible for providing information for the register and maintaining a record of the viruses and infected cell lines used in their laboratories. The maintenance of a central register for the institution/ company/organisation is the responsibility of the IBC. (k) Great care shall be taken to decontaminate spills immediately. The correct disinfectant to use in any given situation depends on the organism being handled and is the responsibility of the Principal Investigator in charge of the work to select an appropriate disinfectant. After each session, work surfaces shall be wiped down with an appropriate disinfectant before ultraviolet decontamination. Where a hood has been used for handling amphotropic retroviruses, subsequent use with non-amphotropic viruses can be undertaken following decontamination with a suitable disinfectant and ultraviolet decontamination. (l) Only trained individuals shall be permitted to handle human-infectious recombinant viruses. It is the responsibility of the Principal Investigator to ensure the proper training of personnel in consultation with the IBC. (m) Under no circumstances should investigators be infecting cultures of their own cells, or of their immediate relatives, or those of other members of the laboratory. (n) Before beginning work with human-infectious (genetically manipulated) viruses where vaccination with the corresponding virus is regarded as an effective means of preventing subsequent infection (e.g. vaccinia, hepatitis), investigators shall be vaccinated. (o) Before beginning work with genetically-modified viruses that are potentially able to infect human cells, investigators are advised to consider lodging a serum sample for subsequent health surveillance. 5. Infection of animals with recombinant viruses (a) Infectious animal viruses unable to infect human cells Viruses of this group are not considered hazardous and accordingly good animal handling practices are appropriate. Infected animals shall be kept in separate cages and be held in the biohazard room separate from non-infected animals. Infected animals should be clearly marked. If possible, the use of micro-isolators should be encouraged to prevent cross-infection. Precautions should be taken to avoid animals escaping and coming into contact with other animals. All waste generated from animals of this group shall be autoclaved before disposal. (b) Viruses with the capacity to infect human cells Animals infected with human-infectious viruses shall be kept in a separate cage which is clearly labelled as containing the particular virus in question. They should be kept in a separate biohazard room from non-infected animals. The main risk is to the handler who shall take great care to avoid being scratched, bitten or exposed to aerosols. Gloves, face mask and protective clothings must be worn to avoid direct contact with tissue and body fluids. Work place should be covered with protective paper which shall be changed regularly. Only trained Appendix - Page 13
staff shall handle these infected animals under the supervision of the Principal Investigator. Precautions should be taken to avoid animals escaping and coming into contact with other animals. All waste should be autoclaved prior to disposal. 6. Gene therapy In projects where viruses are being used to deliver genes to human subjects (gene therapy), the approval from the relevant institutional ethics committees and the Medical Clinical Research Committee (Ministry of Health) should be obtained, unless the therapy has already been established by the MOH as an approved treatment. A separate guideline governs the control of virus production and safety testing procedures in gene therapy experiments. Appendix - Page 14
Page 1 and 2: THE SINGAPORE BIOSAFETY GUIDELINES
Page 3 and 4: APPENDICES Appendix 1 Other Relevan
Page 5 and 6: 1.4 DEFINITIONS OF ABBREVIATIONS Fo
Page 7 and 8: 2.2 EXEMPTIONS 2.2.1 The following
Page 9 and 10: SECTION 3: SUMMARY OF PROCEDURES 3.
Page 11 and 12: 3.3 CATEGORY A - EXPERIMENTS REQUIR
Page 13 and 14: SECTION 4: EXPERIMENTS COVERED BY T
Page 15 and 16: 4.2 CATEGORY B - EXPERIMENTS REQUIR
Page 17 and 18: SECTION 5: ROLES AND RESPONSIBILITI
Page 19 and 20: 5.2.5 Monitoring of Work The IBC sh
Page 21 and 22: • submit a new proposal form to t
Page 23 and 24: • All materials that are genetica
Page 25 and 26: 6.5 SUPPLY OF GENETICALLY MANIPULAT
Page 27 and 28: 6.6.5 The form should contain any r
Page 29 and 30: BLANK PAGE
Page 31 and 32: 3. Worldwide guidelines specific to
Page 33 and 34: xiv. AS 2252.2: 1994: xv. AS 2647:
Page 35 and 36: APPENDIX 2: LIST OF GMAC-APPROVED H
Page 37 and 38: APPENDIX 3: INSTRUCTIONS FOR COMPLE
Page 39 and 40: PROPOSAL FORM FOR ASSESSMENT OF GEN
Page 41 and 42: -----------------------------------
Page 43 and 44: ) Describe the techniques to be emp
Page 45 and 46: ii) Category B iii) Category C C. R
Page 47 and 48: APPENDIX 4: TOXINS For work involvi
Page 49: 4. Procedures for handling viruses
Page 53 and 54: APPENDIX 7: REQUIREMENTS FOR GENETI
Page 55 and 56: equire the provision of a front cov
Page 57 and 58: Signs 10. An automatically-starting
Page 59 and 60: 9. All plants in the plant house sh
Page 61 and 62: APPENDIX 12: PROCEDURES FOR EXPERIM
Page 63 and 64: APPENDIX 13: DESIGN OF ANIMAL FACIL
Page 65 and 66: Other Work Being Performed in the S
Page 67 and 68: permitted in animal rooms. Personne
Page 69 and 70: APPENDIX 15: REQUIREMENTS FOR GENET
Page 71 and 72: APPENDIX 16: REQUIREMENTS FOR INSEC
Page 73 and 74: APPENDIX 17: REQUIREMENTS FOR INSEC
Page 75 and 76: APPENDIX 18: PROCEDURES FOR EXPERIM
Page 77 and 78: From Bio-Security Assurance Arrange
Page 79 and 80: VIRUSES (con’t) Family and genus
Page 81 and 82: PESTS (cont’d) INSECTS MAIN HOST
Page 83 and 84: PESTS (cont’d) NEMATODES MAIN HOS
Page 85 and 86: PESTS (cont’d) NEMATODES MAIN HOS
Page 87 and 88: From the Notifiable Diseases List o
Page 89 and 90: From the Notifiable Diseases List o
Page 91 and 92: APPENDIX 20: GLOSSARY Note: Words a
Page 93 and 94: fusion gamete gene gene therapy gen
Page 95 and 96: polymerase chain reaction prion pro

Biosafety Guidelines For Research On Genetically Modified ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?